8-methoxypsoralen-dna adducts in patients treated with 8-methoxypsoralen and ultraviolet a light

21Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The combination of 8-methoxypsoralen (8-MOP) plus ultraviolet A light (320-400 nm), termed PUVA, is used in the treatment of psoriasis, a hyperproliferative disease of the skin. This treatment results in the formation of specific 8-MOP adducts with cellular DNA. We have previously developed monoclonal antibodies which recognize these 8-MOP photoadducts. We now report the use of these antibodies in an indirect immunofluorescence technique to study human skin biopsies. Nuclei in 3 of 5 skin biopsies from psoriasis patients undergoing PUVA therapy were positive for adducts. The presence of adducts by immunofluorescence did not correlate with plasma levels of 8-MOP. Enzyme-linked immunosorbent assays, used to determine whether 8-MOP photoadducts could be detected in DNA isolated from the lymphocytes of psoriasis patients after PUVA therapy, were negative. © 1989.

Cite

CITATION STYLE

APA

Yang, X. Y., Gasparro, F. P., Deleo, V. A., & Santella, R. M. (1989). 8-methoxypsoralen-dna adducts in patients treated with 8-methoxypsoralen and ultraviolet a light. Journal of Investigative Dermatology, 92(1), 59–63. https://doi.org/10.1111/1523-1747.ep13071224

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free